Related Experiment Video

Updated: Jun 13, 2026

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

Epstein-Barr virus: novel patented therapeutics

Paolo De Paoli1

  • 1Scientific Direction, Centro di Riferimento Oncologico, IRCCS, via Gallini, 2, 33081 Aviano, Italy. dirscienti@cro.it

Expert Opinion on Therapeutic Patents
|April 14, 2010
PubMed
Abstract

Insights

New therapies targeting Epstein-Barr virus (EBV) and associated cancers show promise. Vaccination and cellular therapies are most advanced, while pharmacological approaches are still in early development.

Area of Science:

  • Virology
  • Oncology
  • Immunology

Background:

  • Epstein-Barr virus (EBV) infection and associated cancers lack effective treatments.
  • Targeting EBV protein functions offers potential therapeutic strategies.
  • EBV plays a key role in the pathogenesis of these diseases.

Purpose of the Study:

  • To review current and emerging therapeutic strategies for EBV infection and associated cancers.
  • To identify promising therapeutic targets and approaches for EBV-related diseases.

Main Methods:

  • Comprehensive literature search, including patent publications, focusing on EBV therapeutic options.
  • Review of active immunotherapeutic protocols, adoptive cellular therapies, and pharmacological approaches.
  • Organization and discussion of gathered information on EBV treatments.

Main Results:

  • Numerous promising therapeutic opportunities for EBV-related diseases have been identified.
  • Vaccination protocols and adoptive cellular therapies are the most advanced, reaching Phase I/II clinical trials.
  • Pharmacological approaches targeting EBV are currently limited to laboratory research.

Conclusions:

  • Vaccination and adoptive cellular therapies represent the most advanced therapeutic strategies for EBV and associated cancers.
  • Further research and development are needed for pharmacological approaches to reach clinical application.
  • Interfering with EBV protein functions holds significant potential for treating EBV-associated diseases.

More Related Videos

Isolation and Quantification of Epstein-Barr Virus from the P3HR1 Cell Line09:14

Isolation and Quantification of Epstein-Barr Virus from the P3HR1 Cell Line

Published on: September 28, 2022

Establishment of Epstein-Barr Virus Growth-transformed Lymphoblastoid Cell Lines06:38

Establishment of Epstein-Barr Virus Growth-transformed Lymphoblastoid Cell Lines

Published on: November 8, 2011

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Inhibitors Of Virion Release01:25

Inhibitors Of Virion Release

Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
Inhibitors of Virion Maturation and Assembly01:19

Inhibitors of Virion Maturation and Assembly

As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...